Selecta Biosciences Inc (SELB) Received Consensus Recommendation of “Purchase” by Brokerages

Selecta Biosciences Inc (SELB) Received Consensus Recommendation of “Purchase” by Brokerages

Selecta Biosciences Inc (NASDAQ:SELB) has been given an average rating of “Buy” by the eight analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $20.56.

A number of analysts have recently issued reports on the company. Mizuho restated a “buy” rating and issued a $30.00 target price on shares of Selecta Biosciences in a report on Wednesday, October 17th. BidaskClub lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Stifel Nicolaus assumed coverage on Selecta Biosciences in a report on Friday, September 14th. They issued a “buy” rating and a $24.00 target price for the company. Zacks Investment Research lowered Selecta Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, August 29th. Finally, Janney Montgomery Scott restated a “buy” rating on shares of Selecta Biosciences in a report on Tuesday, October 23rd.

Large investors have recently made changes to their positions in the stock. Millennium Management LLC purchased a new stake in shares of Selecta Biosciences during the second quarter worth $1,583,000. Rhumbline Advisers raised its holdings in shares of Selecta Biosciences by 43.7% during the second quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock worth $222,000 after acquiring an additional 5,103 shares in the last quarter. Artal Group S.A. raised its holdings in shares of Selecta Biosciences by 12.3% during the third quarter. Artal Group S.A. now owns 561,540 shares of the company’s stock worth $8,732,000 after acquiring an additional 61,540 shares in the last quarter. Proxima Capital Management LLC purchased a new stake in shares of Selecta Biosciences during the second quarter worth $1,075,000. Finally, BlackRock Inc. raised its holdings in shares of Selecta Biosciences by 40.4% during the second quarter. BlackRock Inc. now owns 884,564 shares of the company’s stock worth $11,721,000 after acquiring an additional 254,586 shares in the last quarter. Institutional investors and hedge funds own 51.04% of the company’s stock.

Shares of SELB traded down $0.41 during mid-day trading on Wednesday, reaching $5.72. The company’s stock had a trading volume of 116,521 shares, compared to its average volume of 117,312. The firm has a market capitalization of $135.28 million, a P/E ratio of -1.79 and a beta of 1.00. Selecta Biosciences has a 1 year low of $4.74 and a 1 year high of $16.55.

Selecta Biosciences (NASDAQ:SELB) last released its earnings results on Thursday, November 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.08. On average, equities analysts expect that Selecta Biosciences will post -2.92 earnings per share for the current year.

About Selecta Biosciences

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Further Reading: How can you know how many shares are floating?

Related posts

Leave a Comment